Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug
Administration (FDA) has accepted for review the supplemental New Drug
Application (sNDA) for XELJANZ ® (tofacitinib citrate) 5 mg
and 10 mg tablets, a Janus kinase (JAK) inhibitor, the first in a new
class of oral medicines being investigated for the treatment of adult
patients with moderate to severe chronic plaque psoriasis who are
candidates for systemic therapy or phototherapy.
for Pfizer Announces FDA Acceptance For Review Of Supplemental New Drug Application For Oral XELJANZ® (tofacitinib citrate) For Adult Patients With Moderate To Severe Chronic Plaque Psoriasis investment picks